Neil Carleton reshapes breast cancer care for older women — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Neil Carleton, a cancer biologist and first-year resident at Brigham and Women's Hospital, was named a STAT Wunderkind for his work on tailoring breast cancer treatment for older adults, a group that makes up almost half of patients but only 9% of clinical trial participants.
- Carleton's EHR "nudge" — a pop-up reminding surgeons to consider omitting sentinel lymph node biopsies in women 70+ with early-stage cancer — reduced biopsy rates by almost half across eight clinics, even though guidelines against the procedure had existed since 2016.
- Carleton and colleagues at the University of Pittsburgh identified an enzyme that converts estrone to estradiol within tumors, explaining the paradox of how 91% of breast cancers in women 85+ are estrogen-receptor-positive despite lower circulating estrogen after menopause — and pointing to a potential gel or patch-based drug with fewer side effects.
- A ctDNA clinical trial Carleton designed with Natera found that patients with detectable circulating tumor DNA at six months were 30 times more likely to progress, while no patients with undetectable ctDNA progressed — offering a blood-test tool to monitor older women who forgo surgery.
- Carleton's analysis of patient records showed that women 70+ who forwent surgery and relied on primary endocrine therapy had only a 3% breast cancer mortality rate after six years, with 91% achieving tumor control — supporting his mentors' framing that "precision medicine doesn't mean doing more."
- Carleton is now designing a larger ctDNA trial and stays engaged with research at the Lee-Oesterreich lab, where students continue studying the estrogen-converting enzyme he identified.
- Breast cancer biology differs in older patients due to hormone levels and inflammation, and Carleton argues tumors should be treated based on patient-specific factors rather than "age-agnostic" standard protocols.
Why it matters: Older patients make up roughly half of breast cancer cases but only 9% of clinical trial participants, leaving treatment guidelines anchored to younger biology. Carleton's concrete interventions — an EHR nudge that halved unnecessary biopsies and ctDNA markers identifying patients 30 times more likely to progress — give clinicians tools to scale treatment up or down based on individual risk, potentially sparing low-risk women from surgery while escalating care for those who need it.
Ask SkimNews
